3 recruiting, 2 terminated, 1 active not recruiting. 6 Phase 2, 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Recruiting 3, Terminated 2, Active not recruiting 1 |
| Phase 3 | 6 | Recruiting 3, Terminated 2, Active not recruiting 1 |
Follow Netherton Syndrome: new trials by email Literature Review of Netherton Syndrome trials Research Report on Netherton Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome QRX003 - Netherton Syndrome | Phase 2 / Phase 3 | Recruiting | Quoin Pharmaceuticals | 16 | 2026-03-19 | 2026-09-28 |
| Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome QRX003, 4% Lotion - Netherton Syndrome | Phase 2 / Phase 3 | Recruiting | Quoin Pharmaceuticals | 8 | 2025-10-06 | 2026-08-31 |
| A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome Spesolimab - solution for infusion, Placebo matching to spesolimab - solution for infusion, Spesolimab - solution for injection - Netherton Syndrome | Phase 2 / Phase 3 | Terminated | Boehringer Ingelheim | 43 | 2023-06-12 | 2026-03-12 |
| Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome QRX003, 4% Lotion - Netherton Syndrome | Phase 2 / Phase 3 | Recruiting | Quoin Pharmaceuticals | 20 | 2023-03-14 | 2026-08-31 |
| Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome QRX003-2% Lotion, QRX003-4% Lotion QAM, Vehicle - Netherton Syndrome | Phase 2 / Phase 3 | Active not recruiting | Quoin Pharmaceuticals | 30 | 2022-06-23 | 2026-03-16 |
| A Pilot Study of the Efficacy and Safety of Dupilumab Versus Placebo in Patients With Netherton Syndrome Dupilumab Prefilled Syringe, Placebo Prefilled Syringe - Netherton Syndrome | Phase 2 / Phase 3 | Terminated | University Hospital, Toulouse | 10 | 2020-07-23 | 2026-09-21 |
Abnormalities, Multiple (6) · Congenital Abnormalities (6) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6) · Genetic Diseases, Inborn (6) · Ichthyosiform Erythroderma, Congenital (6) · Ichthyosis (6) · Infant, Newborn, Diseases (6) · Keratosis (6) · Skin Abnormalities (6) · Skin Diseases (6) · Skin Diseases, Genetic (6) · Skin and Connective Tissue Diseases (6)
Injections (1) · spesolimab (1)
Quoin Pharmaceuticals (4) · Boehringer Ingelheim (1) · University Hospital, Toulouse (1)
United States (5) · France (2) · United Kingdom (2) · Australia (1) · Bulgaria (1) · China (1) · Germany (1) · Israel (1) · Italy (1) · Japan (1) · Malaysia (1) · Netherlands (1) · Portugal (1) · Switzerland (1)
Tony Andrasfay (2)